Preoperative inflammatory biomarkers SIRI and NLR associate with worse survival in UTUC after RNU
Inflammatory Biomarkers Linked to Outcomes in Upper Tract Urothelial Carcinoma
This systematic review and meta-analysis of 7,346 patients found that preoperative systemic inflammatory biomarkers, specifically SIRI (HR 2…
Specific inflammatory markers in the blood may be linked to survival outcomes for patients with upper tract urothelial carcinoma.
Liquid biopsy guides kidney-sparing decisions in upper tract urothelial carcinoma without replacing standard care
Liquid biopsy helps doctors decide on kidney-sparing care for upper tract urothelial carcinoma
This review discusses liquid biopsy-guided kidney-sparing management for patients with upper tract urothelial carcinoma. The authors note th…
A review shows liquid biopsy adds value to kidney-sparing decisions for upper tract urothelial carcinoma but does not replace standard imagi…
Metachronous non-muscle invasive bladder cancer after UTUC has worse recurrence and progression with BCG than primary disease
Doctors found that bladder cancer returning later has higher risk of coming back again
This systematic review and meta-analysis of 1292 patients found that metachronous non-muscle invasive bladder cancer after upper tract uroth…
A large review shows bladder cancer returning after a previous kidney cancer treatment is more likely to grow back. This group also has a lo…
Meta-analysis finds 3.2% prevalence of germline MMR mutations in patients with upper tract urothelial carcinoma
Study finds 3.2% of upper tract urothelial cancer patients have inherited DNA repair mutations
A systematic review and meta-analysis of 14 studies including 2378 patients with upper tract urothelial carcinoma (UTUC) found a pooled prev…
About 3% of upper tract urothelial cancer patients carry inherited DNA repair mutations that link their cancer to Lynch syndrome and affect …
Research across Cancer
Related studies from across the Cancer family.
ADC resistance in bladder cancer is multifactorial, review finds, with no validated overcoming strategy
New research identifies why some bladder cancer drugs stop working
This systematic review examines mechanisms of resistance to antibody-drug conjugates in locally advanced or metastatic urothelial carcinoma.…
Doctors are uncovering the complex reasons why certain bladder cancer treatments lose their power, helping pave the way for more precise the…
Disitamab vedotin and tislelizumab combination achieved remission of skin metastasis in a patient with bladder carcinoma
Drug Combo Clears Skin Metastasis in Bladder Cancer
This case report describes a 70-year-old man with muscle-invasive bladder carcinoma treated with a combination of disitamab vedotin and tisl…
A man's bladder cancer skin spread vanished after a two-drug combo, but it's just one case.
Pretreatment Creatinine to Cystatin C Ratio Predicts Survival in Gastrointestinal Cancers
Lower Creatinine to Cystatin C Ratio Linked to Shorter Survival
A meta-analysis of 3,073 patients indicates that a lower creatinine-to-cystatin C ratio correlates with significantly poorer survival outcom…
A new analysis suggests that the creatinine-to-cystatin C ratio may help predict survival outcomes for patients with certain digestive tract…
Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection
Cytokine Therapies Show Potential for Treating Canine Cancers
This mini review synthesizes evidence on targeted cytokine delivery platforms, such as IL-12 and IFN-beta, in dogs with various spontaneous …
New research explores how targeted cytokine delivery systems can treat various cancers in dogs and provide data for future human cancer trea…
Systematic review of preclinical CBD effects in canine cancers
Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Systematic review and meta-analysis of disitamab vedotin efficacy in urothelial carcinoma
Researchers Find Disitamab Vedotin Shows Activity In Bladder Cancer
This systematic review and meta-analysis evaluates disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metasta…
A new review suggests the drug disitamab vedotin might work for some bladder cancer patients with low or negative HER2 levels.
Disitamab vedotin plus PD-1 inhibitor showed high response rates in urothelial carcinoma patients across six centers
New Drug Combo Shows Strong Results for Advanced Bladder Cancer
This retrospective cohort study evaluated disitamab vedotin combined with a PD-1 inhibitor in 132 patients with locally advanced or metastat…
A new drug pairing shrank tumors in 71% of advanced bladder cancer patients, even those with diabetes or kidney problems.
Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients
New Treatment Extends Life for Bladder Cancer Patients
This multicenter Phase II study evaluated camrelizumab plus nab-paclitaxel in 60 patients with advanced urothelial carcinoma who progressed …
For years, Mark, 64, thought he’d beaten cancer.
Systematic review of extended versus standard pelvic lymph node dissection in bladder cancer surgery
More Lymph Nodes Removed, Better Survival — But at What Cost?
This systematic review analyzed 993 randomized participants undergoing radical cystectomy for muscle-invasive or treatment-refractory non-mu…
This surgery could help some live longer, but it’s not risk-free.
Magrolimab plus docetaxel shows limited efficacy in metastatic lung and urothelial cancers
New Drug Combo Fails to Shrink Tough Lung and Bladder Cancers
This cohort study evaluated magrolimab plus docetaxel in patients with metastatic non-small cell lung cancer, small cell lung cancer, and ur…
This study shows that adding a new drug to standard chemotherapy did not help patients with advanced lung or bladder cancer live longer or s…